Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses PRME in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PRME in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Allan Reine | $606,212 | $0 | $0 | $2,828,798 | $402,000 | $0 | $57,177 | $3,894,187 |
| Chief Executive Officer | ||||||||
| Keith Gottesdiener | 259,568 | 0 | 0 | 1,185,802 | 0 | 0 | 762,400 | 2,207,770 |
| Former President and Chief Executive Officer | ||||||||
| Ann Lee | 505,375 | 0 | 0 | 790,075 | 243,960 | 0 | 10,706 | 1,550,116 |
| Chief Technical Officer | ||||||||
| Jeremy Duffield | 268,271 | 0 | 0 | 668,600 | 0 | 0 | 380,926 | 1,317,797 |
| Former Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Allan Reine | $3,894,187 | — | — | — |
| Keith Gottesdiener | 2,207,770 | — | — | — |
| Ann Lee | 1,550,116 | — | — | — |
| Jeremy Duffield | 1,317,797 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David P. Schenkein | Director | 2026-06-05 | A | 75,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Marrazzo | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Nelsen | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kaye I. Foster-Cheek | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Chung | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Cahill | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kelly | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Allan Reine, M.D. | OPTION | 2025-02-27 | — | 275,000 | 275,000 | — | $471,598 |
| Allan Reine, M.D. | OPTION | 2025-08-01 | — | 850,000 | 850,000 | — | 445,801 |
| Keith Gottesdiener | OPTION | 2025-02-28 | — | — | — | — | 500,000 |
| Jeremy Duffield | OPTION | 2025-02-27 | — | — | — | — | 275,000 |
| Ann Lee | OPTION | 2025-08-01 | — | — | — | — | 180,995 |
| Ann Lee | OPTION | 2025-02-27 | — | — | — | — | 275,000 |
| Allan Reine, M.D. | OPTION | 2025-05-19 | — | 2,000,000 | 2,000,000 | — | 1,911,400 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Allan Reine, M.D. | $0 | $0 | $2,828,799 | 0.0% |
| Keith Gottesdiener | 0 | 0 | 500,000 | 0.0% |
| Jeremy Duffield | 0 | 0 | 275,000 | 0.0% |
| Ann Lee | 0 | 0 | 455,995 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ann Lee | Option | 56,561 | 4.04 | — |
| Ann Lee | Option | 217,709 | 2.42 | — |
| Keith Gottesdiener | Option | 155,544 | 12.3 | — |
| Keith Gottesdiener | Option | 395,834 | 2.52 | — |
| Keith Gottesdiener | Option | 54,167 | 8.32 | — |
| Ann Lee | Option | 98,039 | 4.04 | — |
| Ann Lee | Option | 17,966,867 | 3.76 | — |
| Allan Reine | Option | 2,000,000 | 1.34 | — |
| Allan Reine | Option | 217,709 | 2.42 | — |
| Ann Lee | Option | 98,039 | 8.49 | — |
| Allan Reine | Option | 312,500 | 4.04 | — |
| Ann Lee | Option | 56,561 | 12.3 | — |
Our executive compensation program is designed to attract, motivate and retain key employees who we believe best represent our values and can make significant contributions towards achieving our purpose of delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying our Prime Editing technology. Our program's purpose is to incentivize them based on the achievement of key performance goals, and to align their interests with the interests of our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-08-01 | 71,563,193 | 13,491,029 | 95,830 | 84.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-08-01 | 84.14%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey D. MarrazzoEmployee director · Board Chair | $0 | $0 | $348,821 | — | $95,161 | $443,982 |
| Michael KellyIndependent · Audit (Chair) | 65,000 | 0 | 111,611 | 0 | 0 | 176,611 |
| Kaye FosterIndependent · Compensation (Chair) | 60,000 | 0 | 111,891 | 0 | 0 | 171,891 |
| Wendy Chung, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance | 60,000 | 0 | 111,611 | 0 | 0 | 171,611 |
| David Schenkein, M.DIndependent · Compensation · Nominating and Corporate Governance (Chair) | 62,500 | 0 | 83,456 | 0 | 0 | 145,956 |
| Thomas Cahill, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance | 60,000 | 0 | 83,456 | 0 | 0 | 143,456 |
| Robert NelsenIndependent · Compensation | 52,500 | 0 | 83,456 | 0 | 0 | 135,956 |
| Allan Reine, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $360,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $95,161 |
| Total cost of the board | $455,161 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Prime Medicine | 2025 | Allan Reine | $606,212 | $0 | $2,828,798 | $402,000 | $3,894,187 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Allan Reine | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “2025 Summary Compensation Table”. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |
| 2 | Section 01, Keith Gottesdiener | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “2025 Summary Compensation Table”. As printed: 2,207,770. Filing ↗machine: r4 · c42 · span 291171–291180 |
| 3 | Section 01, Ann Lee | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “2025 Summary Compensation Table”. As printed: 1,550,116. Filing ↗machine: r6 · c42 · span 297131–297140 |
| 4 | Section 01, Jeremy Duffield | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “2025 Summary Compensation Table”. As printed: 1,317,797. Filing ↗machine: t15 · r8 · c19 · span 301287–301296 |
| 5 | Section 03, Allan Reine, M.D. OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r2 · c10 · span 195599–195606 |
| 6 | Section 03, Allan Reine, M.D. OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r8 · c10 · span 213485–213492 |
| 7 | Section 03, Keith Gottesdiener OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r5 · c4 · span 203458–203465 |
| 8 | Section 03, Jeremy Duffield OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r4 · c4 · span 200486–200493 |
| 9 | Section 03, Ann Lee OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r9 · c4 · span 215340–215347 |
| 10 | Section 03, Ann Lee OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r3 · c4 · span 197504–197511 |
| 11 | Section 03, Allan Reine, M.D. OPTION | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r6 · c10 · span 207534–207543 |
| 12 | Section 07, pay ratio | 10-K | 2026-03-03 | 0001628280-26-013569 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 13 | Section 08, Jeffrey D. Marrazzo | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 443,982. Filing ↗ |
| 14 | Section 08, Michael Kelly | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 176,611. Filing ↗ |
| 15 | Section 08, Kaye Foster | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 171,891. Filing ↗ |
| 16 | Section 08, Wendy Chung, M.D., Ph.D | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 171,611. Filing ↗ |
| 17 | Section 08, David Schenkein, M.D | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 145,956. Filing ↗ |
| 18 | Section 08, Thomas Cahill, M.D., Ph.D | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 143,456. Filing ↗ |
| 19 | Section 08, Robert Nelsen | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 135,956. Filing ↗ |
| 20 | Section 08, Allan Reine, M.D | DEF 14A | 2026-04-23 | 0001628280-26-026697 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 02, David P. Schenkein 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041579 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Jeffrey D. Marrazzo 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041575 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Robert Nelsen 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041572 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Kaye I. Foster-Cheek 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041566 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Wendy Chung 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041560 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Thomas Cahill 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041553 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Michael Kelly 2026-06-05 | Form 4 | 2026-06-08 | 0001628280-26-041569 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 06, 2025 vote | Form 8-K | 2025-08-05 | 0001628280-25-037840 | Item 5.07 · say-on-pay result. As reported: 84.14% (votes for as printed: 71,563,193). Filing ↗ |
| 29 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 30 | Section 09b board cost (computed) | Computed | — | computed | Cash 360,000 + equity 0 + all other 95,161 = 455,161, summed across the director compensation table rows.machine: formula: Σ = 455,161 |
| 31 | Prime Medicine (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026697 | CEO total compensation as printed in Prime Medicine's own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |